GeneDx Holdings Corp.WGSEarnings & Financial Report
GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...
WGS Q3 2025 Key Financial Metrics
Revenue
$116.7M
Gross Profit
$84.5M
Operating Profit
$-3.3M
Net Profit
$-7.6M
Gross Margin
72.4%
Operating Margin
-2.8%
Net Margin
-6.5%
YoY Growth
51.9%
EPS
$-0.27
Financial Flow
GeneDx Holdings Corp. Q3 2025 Financial Summary
GeneDx Holdings Corp. reported revenue of $116.7M for Q3 2025, with a net profit of $-7.6M (-6.5% margin). Cost of goods sold was $32.2M, operating expenses totaled $87.8M.
Key Financial Metrics
| Total Revenue | $116.7M |
|---|---|
| Net Profit | $-7.6M |
| Gross Margin | 72.4% |
| Operating Margin | -2.8% |
| Report Period | Q3 2025 |
GeneDx Holdings Corp. Annual Revenue by Year
GeneDx Holdings Corp. annual revenue history includes year-by-year totals (for example, 2024 revenue was $305.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $305.4M |
| 2023 | $202.6M |
| 2022 | $234.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.4M | $62.4M | $70.5M | $76.9M | $95.6M | $87.1M | $102.7M | $116.7M |
| YoY Growth | -6.4% | 44.7% | 44.8% | 44.2% | 66.6% | 39.6% | 45.6% | 51.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $418.8M | $394.5M | $389.1M | $408.8M | $419.4M | $446.4M | $463.9M | $493.9M |
| Liabilities | $190.7M | $187.3M | $195.1M | $204.3M | $174.1M | $189.0M | $186.7M | $201.6M |
| Equity | $228.0M | $207.2M | $194.0M | $204.5M | $245.2M | $257.4M | $277.1M | $292.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.9M | $-16.4M | $-4.5M | $-4.4M | $-3.2M | $10.2M | $10.4M | $15.8M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M